| dc.contributor |
Swiss Tropical Institute, Basel. |
|
| dc.creator |
Schmid, C |
|
| dc.creator |
Richer, M |
|
| dc.creator |
Bilenge, C M M |
|
| dc.creator |
Josenando, T |
|
| dc.creator |
Chappuis, F |
|
| dc.creator |
Manthelot, C R |
|
| dc.creator |
Nangouma, A |
|
| dc.creator |
Doua, F |
|
| dc.creator |
Asumu, P |
|
| dc.creator |
Simarro, P |
|
| dc.creator |
Burri, C |
|
| dc.date |
2005-06-01 |
|
| dc.date.accessioned |
2017-01-31T07:11:44Z |
|
| dc.date.available |
2017-01-31T07:11:44Z |
|
| dc.identifier |
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). 2005, 191 (11):1922-31 J. Infect. Dis. |
|
| dc.identifier |
0022-1899 |
|
| dc.identifier |
15871127 |
|
| dc.identifier |
10.1086/429929 |
|
| dc.identifier |
http://hdl.handle.net/10144/33073 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/33073 |
|
| dc.identifier |
Journal of Infectious Diseases |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/33073 |
|
| dc.description |
BACKGROUND: Treatment of late-stage human African trypanosomiasis (HAT) with melarsoprol can be improved by shortening the regimen. A previous trial demonstrated the safety and efficacy of a 10-day treatment schedule. We demonstrate the effectiveness of this schedule in a noncontrolled, multinational drug-utilization study. METHODS: A total of 2020 patients with late-stage HAT were treated with the 10-day melarsoprol schedule in 16 centers in 7 African countries. We assessed outcome on the basis of major adverse events and the cure rate after treatment and during 2 years of follow-up. RESULTS: The cure rate 24 h after treatment was 93.9%; 2 years later, it was 86.2%. However, 49.3% of patients were lost to follow-up. The overall fatality rate was 5.9%. Of treated patients, 8.7% had an encephalopathic syndrome that was fatal 45.5% of the time. The rate of severe bullous and maculopapular eruptions was 0.8% and 6.8%, respectively. CONCLUSIONS: The 10-day treatment schedule was well implemented in the field and was effective. It reduces treatment duration, drug amount, and hospitalization costs per patient, and it increases treatment-center capacity. The shorter protocol has been recommended by the International Scientific Council for Trypanosomiasis Research and Control for the treatment of late-stage HAT caused by Trypanosoma brucei gambiense. |
|
| dc.language |
en |
|
| dc.publisher |
Infectious Diseases Society of America and University of Chicago Press |
|
| dc.relation |
http://www.journals.uchicago.edu/toc/jid |
|
| dc.rights |
Archived on this site with permission and copyright 2005 by the Infectious Diseases Society of America |
|
| dc.title |
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). |
|